Tango Therapeutics, Inc. (TNGX) Tops Q3 EPS by 10c
Tweet
Share
E-mailGet Alerts TNGX Hot Sheet
Join SI Premium – FREE
Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q3 EPS of ($0.27), $0.10 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $11.61 million versus the consensus estimate of $8.07 million.
For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA maintains underperform ratings on six BDC stocks
- Boeing names Ryan Shedd as new SVP and controller
- Cytek faces $56M damages award in Beckman Coulter patent case
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
